Rethinking downstream process development for the next generation of biologics

How can downstream processing keep pace with increasingly complex biologics? Greater selectivity and process intensification could help build more flexible and efficient purification strategies

The rapid evolution of biologic therapeutics has been reshaping expectations for downstream process development. As pipelines expand beyond conventional monoclonal antibodies (mAbs) to include bispecific antibodies (BsAbs), antibody fragments and increasingly complex biologic formats, manufacturers are under pressure to develop purification strategies that are robust and scalable but also flexible enough to accommodate greater molecular diversity.

In the past, downstream processing for biologics relied on relatively standardised platform approaches. Traditional mAbs shared predictable structural characteristics, enabling developers to establish proven purification workflows built around affinity capture and polishing steps that could be applied with limited modification across multiple products. That consistency supported the rapid growth of biologics manufacturing over the last two decades.

Today, the industry is entering a new phase. Complex biologics are creating new therapeutic opportunities, particularly in oncology, autoimmune disease and rare disease treatment, while also introducing significant challenges in process development. Molecules that incorporate multiple binding domains, engineered scaffolds or highly customised structures often behave differently during purification compared with traditional mAbs, resulting in impurity profiles and stability considerations that cannot always be addressed using legacy process assumptions.

This growing complexity is forcing manufacturers to rethink how downstream processes are designed and optimised. Rather than relying solely on established platform methods developed for conventional mAbs, downstream process development is becoming more data-driven and collaborative, with purification strategies increasingly tailored to the specific structural and functional characteristics of each molecule.

One of the defining challenges in modern downstream development is molecular heterogeneity. BsAbs, for example, can generate impurities that closely resemble the target product in size, charge and hydrophobicity, making separation significantly more difficult than with traditional mAbs. Key downstream challenges for BsAbs include:

• Mispaired chains, partially assembled intermediates and aggregates that are difficult to separate from the target molecule

• Greater sensitivity to process conditions, particularly acidic elution environments that can increase aggregation or degradation risk

• Increased process complexity when early purification steps lack sufficient selectivity, often requiring additional polishing stages or tighter process controls

• Higher operational demands linked to increased buffer consumption, water use and extended development timelines.

For process development teams, the focus is increasingly on developing purification strategies that deliver high resolution while also supporting process intensification by reducing unit operations, minimising buffer consumption and improving manufacturing efficiency across the product life cycle.

As biologics become more complex, even more emphasis is placed on selectivity in downstream process design. While traditional purification approaches prioritised strong binding capacity and broad applicability, modern downstream development increasingly depends on the ability to differentiate between structurally similar species. This is driving greater interest in domain-targeted affinity approaches and optimised chromatographic media that can remove closely related impurities earlier in the purification process.

Improved selectivity during capture can simplify polishing strategies, reduce the number of unit operations and support greater process robustness and scale-up predictability. As a result, downstream teams are placing greater emphasis on selectivity and on broader resin attributes that affect process performance and manufacturability, including elution behaviour, consistency, protease resistance and compatibility with intensified manufacturing approaches.

Alongside growing molecular complexity, manufacturers are also facing increasing pressure to improve productivity and sustainability. Biopharmaceutical facilities are expected to deliver higher throughput while reducing resource consumption and controlling cost of goods. Several trends are shaping process intensification strategies in downstream operations:

• High-capacity chromatography resins and continuous processing approaches that enable larger volumes to be processed in less time

• Improved column efficiency that reduces buffer requirements and minimises process footprints

• More durable resins with longer operational lifetimes that help reduce downtime and replacement costs

• Jetted resin technologies that improve particle uniformity, reduce backpressure and support more efficient purification cycles

• Greater focus on sustainability metrics such as water usage, chemical waste generation and energy consumption.

Importantly, process intensification depends on maintaining product quality and process robustness while efficiently scaling operations across the entire purification workflow.

One of the biggest shifts in downstream process development is the earlier integration of molecule design, upstream development and purification strategy. Rather than treating purification as a later-stage activity, manufacturers are increasingly incorporating downstream considerations earlier in development, recognising that molecular engineering decisions can directly influence aggregation behaviour, impurity profiles and purification complexity.

Early collaboration between molecular biologist, upstream scientists, downstream teams and technology partners helps identify potential purification challenges before they become scale-up risks. This integrated approach supports faster development timelines, reduces the likelihood of late-stage process redesign and provides access to specialised expertise as biologic modalities continue to diversify. For manufacturers, this collaborative model improves agility as technologies and therapeutic formats continue to evolve.

The pace of innovation in biologics development shows no signs of slowing. Multi-specific antibodies, fusion proteins and other advanced modalities are expected to place even greater demands on downstream processing in the years ahead.

Meeting those demands will require continued evolution in process development philosophy. Platform approaches will remain valuable where appropriate, but future downstream strategies will increasingly depend on flexibility, selectivity and integrated process understanding. Manufacturers that invest early in smarter purification design, process intensification and collaborative development models will be better positioned to manage both technical complexity and commercial pressure.

Downstream process development is becoming far more than a manufacturing function. It is emerging as a strategic enabler of biologic innovation, playing a critical role in determining whether advanced therapies can be produced efficiently, consistently and at commercial scale. As the next generation of biologics moves towards commercialisation, the ability to align purification strategy with molecular complexity will become an increasingly important differentiator across the biopharma industry.